Clinical Trials


COM701 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of COM701 as monotherapy and in combination with a PD-1 inhibitor. Additional endpoints include evaluation of PK/PD and preliminary clinical activity in certain tumor types such as NSCLC, breast, ovarian endometrial cancer. Preclinical data demonstrate that these tumor types express a high level of the biomarkers PVRIG and PVRL2.

The Phase 1 study is currently enrolling patients in the United States. Additional Information on the COM701 Phase 1 clinical trial can be found here.


Max 1mb, accepted formats: pdf, doc, docx, rtf
Message Sent. Thank You!